ArticleInternational journal of nanomedicine2010
Andrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluations.
Article in International journal of nanomedicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Andrographolide as a Promising Diterpenoid Scaffold Against the Neurotropic NematodePharmaceuticals (Basel, Switzerland) · 2026Article
- Andrographolide and Its Derivatives: A Comprehensive Review of Anti-Infective Properties and Clinical Potential.Molecules (Basel, Switzerland) · 2025Review
- Enhancement of Cognitive Function by Andrographolide-Loaded Lactose β-Cyclodextrin Nanoparticles: Synthesis, Optimization, and Behavioural Assessment.Pharmaceuticals (Basel, Switzerland) · 2024Article
- A novel outlook in the delivery of artemisinin: production and efficacy in experimental visceral leishmaniasis.Pathogens and global health · 2024Article
- The Prospects of Phytomedicines and Nanomedicines to Treat Leishmaniasis: A Comprehensive Review.Current drug research reviews · 2024Review
- UtilizingFrontiers in nutrition · 2023Article
- Synthesis and appraisal of dalbergin-loaded PLGA nanoparticles modified with galactose against hepatocellular carcinoma:Frontiers in pharmacology · 2022Article
- Nanoparticles: New agents toward treatment of leishmaniasis.Parasite epidemiology and control · 2020Review
- Gold-Silver Bimetallic Nanoparticles Reduced with Herbal Leaf Extracts Induce ROS-Mediated Death in Both Promastigote and Amastigote Stages ofACS omega · 2020Article
- Antileishmanial Activity and Synergistic Effects of Amphotericin B Deoxycholate with Allicin and Andrographolide againstPathogens (Basel, Switzerland) · 2020Article
- Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges.Nanomaterials (Basel, Switzerland) · 2019Review
- Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems.Pathogens (Basel, Switzerland) · 2019Review
- In vitro-in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin.International journal of nanomedicine · 2019Article
- Andrographolide-loaded silk fibroin nanoparticles.RSC advances · 2018Article
- Development of Andrographolide-Carboxymethyl Chitosan Nanoparticles: Characterization,Turkish journal of pharmaceutical sciences · 2018Article
- Poly(lactic-International journal of nanomedicine · 2018Article
- Development of Nanoemulsions to Enhance the Antileishmanial Activity ofBioMed research international · 2018Article
- Designed Synthesis of Nanostructured Magnetic Hydroxyapatite Based Drug Nanocarrier for Anti-Cancer Drug Delivery toward the Treatment of Human Epidermoid Carcinoma.Nanomaterials (Basel, Switzerland) · 2017Article
- Nanostructured delivery systems with improved leishmanicidal activity: a critical review.International journal of nanomedicine · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Andrographolide (AG) is a diterpenoid lactone isolated from the leaves of Andrographis paniculata. AG is a potent and low-toxicity antileishmanial agent. Chemotherapy applications of AG are, however, seriously constrained because of poor bioavailability, short plasma half-life, and inappropriate tissue localization. Nanoparticulation of AG was therefore envisaged as a possible solution. AG nanoparticles (AGnp) loaded in 50:50 poly(DL-lactide-co-glycolic acid) were prepared for delivery into the monocyte-macrophage cells infested with the amastigote form of leishmanial parasite for evaluation in the chemotherapy of leishmaniasis. Particle characteristics of AGnp were optimized by proportionate application of a stabilizer, polyvinyl alcohol (PVA). Physicochemical characterization of AGnp by photon correlation spectroscopy exhibited an average particle size of 173 nm and zeta potential of -34.8 mV. Atomic force microscopy visualization revealed spherical nanoparticles with a smooth surface. Antileishmanial activity was found to be significant for the nanoparticle preparation with 4% PVA (IC₅₀) 34 μM) in about one-fourth of the dosage of the pure compound AG (IC₅₀) 160 μM). AGnp therefore have significant potential to target the infested macrophage cells and prove valuable in chemotherapy of neglected tropical diseases such as leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.